期刊
FASEB JOURNAL
卷 28, 期 1, 页码 373-381出版社
FEDERATION AMER SOC EXP BIOL
DOI: 10.1096/fj.13-236570
关键词
protein transduction domain; inflammation; MMP; gene therapy
资金
- Arthritis Research UK [17428, 17559, 17208, 18401]
- British Heart Foundation [PG/09/093]
- Medical Research Council [G0800795]
- National Multiple Sclerosis Society USA
- Wellcome Trust [073271]
- MRC [G0800795] Funding Source: UKRI
Gene therapy is a powerful approach to treat disease locally. However, if the therapeutic target is intracellular, the therapeutic will be effective only in the cells where the therapeutic gene is delivered. We have engineered a fusion protein containing an intracellular inhibitor of the transcription factor NF-B pathway that can be effectively secreted from producing cells. This fusion protein is cleaved extracellularly by metalloproteinases allowing release of a protein transduction domain (PTD) linked to the NF-B inhibitor for translocation into neighboring cells. We show that engineered molecules can be efficiently secreted (>80%); are cleaved with matrix metalloprotease-1; inhibit NF-B driven transcription in a biological assay with a human reporter cell line; and display significant inhibition in mouse paw inflammation models when delivered by lentivirus or secreting cells. No inhibition of NF-B transcription or therapeutic effect was seen using molecules devoid of the PTD and NF-B inhibitory domains. By creating a fusion protein with an endogenous secretion partner, we demonstrate a novel approach to efficiently secrete PTD-containing protein domains, overcoming previous limitations, and allowing for potent paracrine effects.Koutsokeras, A., Purkayashta, N., Rigby, A., Subang, M. C., Sclanders, M., Vessillier, S., Mullen, L., Chernajovsky, Y., Gould, D. Generation of an efficiently secreted, cell penetrating NF-B inhibitor.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据